Blood filter device offers new hope for heart failure patients awaiting LVAD
NCT ID NCT03836482
First seen Nov 01, 2025 · Last updated May 23, 2026 · Updated 33 times
Summary
This study tests a device called the Selective Cytopheretic Device (SCD) in 20 ICU patients with severe heart failure and worsening kidney function. The device filters the blood to reduce inflammation, which may improve heart and kidney function enough to make patients eligible for a life-saving heart pump (LVAD). Participants receive daily 4-hour treatments for up to 6 days and are followed for 6 months to check safety and benefits.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE ON CHRONIC SYSTOLIC CONGESTIVE HEART FAILURE are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
University of Michigan
RECRUITINGAnn Arbor, Michigan, 48109, United States
Contact Phone: •••-•••-••••
Conditions
Explore the condition pages connected to this study.